Phase 1 Study of BMS-986488 Alone and in Combination With Other Drugs for Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating BMS-986488, alone and in combination with other drugs, in patients with advanced malignant tumors. This early-phase study aims to determine if these treatments are safe, tolerable, and show anti-cancer activity in various solid tumor types, including clear-cell renal cell carcinoma, ovarian cancer, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The study is sponsored by Bristol-Myers Squibb and involves participants with specific tumor mutations and measurable disease. Participants receive BMS-986488 as monotherapy or combined with adagrasib, cetuximab, or nivolumab in different parts of the study. Dosing schedules involve specified doses on particular days, with study parts designed to assess different drug combinations. The trial follows a sequential model without randomization or masking. During the study, participants are monitored for adverse events, serious adverse events, and dose-limiting toxicities up to approximately 100 days after the last dose. Researchers assess drug concentrations through blood tests and evaluate tumor response and disease control over up to 52 weeks after treatment ends. The total participation duration may vary depending on treatment cycles and follow-up assessments.

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors